The pursuit of novel peptide therapeutics just received a significant boost, with Malvern, PA-based 20n Bio announcing it has secured $7.5M in seed funding. Launched in 2021, the VC-backed startup is dedicated to designing and screening cyclic peptides, aiming to address unmet medical needs.
20n Bio leverages high-throughput screening and computing to generate peptide drugs with desired biophysical, functional, and pharmacological properties, a strategy it hopes will unlock new solutions for complex health challenges.














